PGEN Stock Overview
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.40 |
| 52 Week High | US$1.88 |
| 52 Week Low | US$0.84 |
| Beta | 1.77 |
| 1 Month Change | 0.36% |
| 3 Month Change | 0.72% |
| 1 Year Change | 23.89% |
| 3 Year Change | -82.32% |
| 5 Year Change | -67.67% |
| Change since IPO | -94.34% |
Recent News & Updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28
Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Recent updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
Nov 10Precigen names Rutul Shah as chief operating officer
Sep 21Circling Back On Precigen
Aug 23Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Aug 10Precigen Q2 2022 Earnings Preview
Aug 07Precigen to sell Trans Ova Genetics for $170M upfront
Jul 05Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
May 10The Prognosis On Precigen
Jan 05Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Dec 31Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher
Aug 12Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt
Jul 16Time To Worry? Analysts Are Downgrading Their Precigen, Inc. (NASDAQ:PGEN) Outlook
Mar 03What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?
Feb 12
Precigen announces positive preliminary data from early-stage PRGN-2009 cancer study
Jan 13Precigen on go with Phase I study of PRGN-2012 in respiratory papillomatosis
Jan 05Shareholder Returns
| PGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | -2.5% | -3.2% |
| 1Y | 23.9% | -3.7% | 19.3% |
Return vs Industry: PGEN exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PGEN exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| PGEN volatility | |
|---|---|
| PGEN Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: PGEN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
| PGEN fundamental statistics | |
|---|---|
| Market cap | US$343.51m |
| Earnings (TTM) | -US$95.90m |
| Revenue (TTM) | US$6.23m |
56.0x
P/S Ratio-3.6x
P/E RatioIs PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGEN income statement (TTM) | |
|---|---|
| Revenue | US$6.23m |
| Cost of Revenue | US$54.73m |
| Gross Profit | -US$48.51m |
| Other Expenses | US$47.40m |
| Earnings | -US$95.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | -779.25% |
| Net Profit Margin | -1,540.63% |
| Debt/Equity Ratio | 0% |
How did PGEN perform over the long term?
See historical performance and comparison